X - Linked Hypophosphatemic Rickets: A diagnostic and therapeutic challenge
DOI:
https://doi.org/10.17533/udea.iatreia.92Keywords:
hypophosphatemia, child, osteomalacia, ricketAbstract
X-linked hypophosphatemia is a genetic disorder caused by PHEX gene mutations, which affects the encoding of a metalloprotease whose function is to inhibit fibroblastic growth factor —23 (FGF-23), promoting phosphate renal loss.
Following we describe the case of a teenager diagnosed with a PHEX gene mutation. The same genetic alteration was found in the mother of the patient, considering a spontaneous mutation that was transmitted to her son, which makes the case, even rarer, where the diagnostic challenge needs to overcome administrative, economic and social difficulties. A timely diagnosis and treatment could help optimize the final
height and minimize the skeletal deformities presented in both the mother and the child. Currently, there is a traditional treatment and a novel one that was ordered for the pediatric patient in this report.
Downloads
References
(1) Carpenter TO, Imel EA, Holm IA, Jan De Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26:1381–8. DOI 10.1002/jbmr.340.
(2) Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: Prevalence, biochemical data and treatment. Endocr J. 2015;62:811–6. DOI 10.1507/endocrj.EJ15-0275.
(3) Ma SL, Vega-Warner V, Gillies C, Sampson MG, Kher V, Sethi SK, et al. Whole exome sequencing reveals novel PHEX splice site mutations in patients with hypophosphatemic rickets. PLoS One. 2015;10:1–12. DOI 10.1371/journal.pone.0130729.
(4) Li SS, Gu JM, Yu WJ, He JW, Fu WZ, Zhang ZL. Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets. Int J Mol Med. 2016;38:1703–14. DOI 10.3892/ijmm.2016.2796.
(5) Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019;15:435–55. DOI 10.1038/s41581-019-0152-5.
(6) Saito T, Nishii Y, Yasuda T, Ito N, Suzuki H, Igarashi T, et al. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene. Eur J Endocrinol. 2009;161:647–51. DOI 10.1530/EJE-09-0261.
(7) Lee JY, Imel EA. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev. 2013;10:367–79.
(8) Gonciulea AR, Jan De Beur SM. Fibroblast Growth Factor 23–Mediated Bone Disease. Endocrinol Metab Clin North Am. 2017;46:19–39. DOI 10.1016/j.ecl.2016.09.013.
(9) Forero-Delgadillo JM, Cleves D, Ochoa V, Londoño-Correa H, Restrepo JM, Nastasi-Catanese JA, et al. PHEX Gene Mutation in a Patient with X-Linked Hypophosphatemic Rickets in a Developing Country. Appl Clin Genet. 2020;13:57–62. DOI 10.2147/tacg.s232448.
(10) Morey M, Castro-Feijóo L, Barreiro J, Cabanas P, Pombo M, Gil M, et al. Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2Dserum levels are associated with PHEX mutation type. BMC Med Genet. 2011;12:1–11. DOI 10.1186/1471-2350-12-116.
(11) Kinoshita Y, Fukumoto S. X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: Prospect for new treatment. Endocr Rev. 2018;39:274–91. DOI 10.1210/er.2017-00220.
(12) Underland L, Markowitz M, Gensure R. Calcium and phosphate hormones: Vitamin D, parathyroid hormone, and fibroblast growth factor 23. Pediatr Rev. 2020;41:3–11. DOI 10.1542/pir.2018-0065.
(13) Pavone V, Testa G, Gioitta Iachino S, Evola FR, Avondo S, Sessa G. Hypophosphatemic rickets: etiology, clinical features and treatment. Eur J Orthop Surg Traumatol. 2015;25:221–6. DOI 10.1007/s00590-014-1496-y.
(14) Bitzan M, Goodyer PR. Hypophosphatemic Rickets. Pediatr Clin North Am. 2019;66:179–207. DOI 10.1016/j.pcl.2018.09.004.
(15) Foster BL, Nociti FH, Somerman MJ. The rachitic tooth. Endocr Rev. 2014;35:1–34. DOI 10.1210/er.2013-1009.
(16) Hawley S, Shaw NJ, Delmestri A, Prieto-Alhambra D, Cooper C, Pinedo-Villanueva R, et al. Prevalence and mortality of individuals with X-linked hypophosphataemia: A United Kingdom real world data analysis. J Clin Endocrinol Metab. 2020;105:1–8. DOI 10.1210/clinem/dgz203.
(17) Carpenter TO, Whyte MP, Imel EA, Boot AM, Högler W, Linglart A, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378:1987–98. DOI 10.1056/NEJMoa1714641.
(18) Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, et al. Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7:189–99. DOI 10.1016/S2213-8587(18)30338-3.
(19) Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet Diabetes Endocrinol. 2019;393:2416–27. DOI 10.1016/S0140-6736(19)30654-3.
(20) Martín Ramos S, Gil-Calvo M, Roldán V, Castellano Martínez A, Santos F. Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia. Front Pediatr. 2020;8:1–5. DOI 10.3389/fped.2020.00048.
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
